Abstrakt

Przypisy

• 1. Aragane Y., Maeda A., Cui C.Y., Tezuka T., Kaneda Y., Schwarz T.:Inhibition of growth of melanoma cells by CD95 (Fas/APO-1) genetransfer in vivo. J. Invest. Dermatol., 2000; 115: 1008-1014
  Google Scholar
• 2. Bendelac A., Savage P.B., Teyton L.: The biology of NKT cells.Annu. Rev. Immunol., 2007; 25: 297-336
  Google Scholar
• 3. Bojarska-Junak A., Tabarkiewicz J., Roliński J.: NKT cells: theirdevelopment, mechanisms and effects of action. Postepy Hig. Med.Dośw., 2013; 67: 65-78
  Google Scholar
• 4. Chen B., Zhang D., Zhou J., Li Q., Zhou L., Li S.M., Zhu L., Chou K.Y.,Zhou L., Tao L., Lu L.M.: High CCR6/CCR7 expression and Foxp3+ Tregcell number are positively related to the progression of laryngealsquamous cell carcinoma. Oncol. Rep., 2013; 30: 1380-1390
  Google Scholar
• 5. De Santo C., Salio M., Masri S.H., Lee L.Y., Dong T., Speak A.O.,Porubsky S., Booth S., Veerapen N., Besra G.S., Gröne H.J., Platt F.M.,Zambon M., Cerundolo V.: Invariant NKT cells reduce the immunosuppressiveactivity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J. Clin. Invest., 2008;118: 4036-4048
  Google Scholar
• 6. Klatka J., Grywalska E., Klatka M., Rahnama M., Polak A., RolinskiJ.: Expression of CD200 and CD200R regulatory molecules on theCD83+ monocyte-derived dendritic cells generated from patientswith laryngeal cancer. Folia Histochem. Cytobiol., 2013; 51: 59-65
  Google Scholar
• 7. Marschner A., Rothenfusser S., Hornung V., Prell D., Krug A., KerkmannM., Wellisch D., Poeck H., Greinacher A., Giese T., Endres S.,Hartmann G.: CpG ODN enhance antigen-specific NKT cell activationvia plasmacytoid dendritic cells. Eur. J. Immunol., 2005; 35: 2347-2357
  Google Scholar
• 8. Matsuda J.L., Mallevaey T., Scott-Browne J., Gapin L.: CD1d-restrictediNKT cells, the ‘Swiss-Army knife’ of the immune system.Curr. Opin. Immunol., 2008; 20: 358-368
  Google Scholar
• 9. Molling J.W., Langius J.A., Langendijk J.A., Leemans C.R., BontkesH.J., van der Vliet H.J., von Blomberg B.M., Scheper R.J., van den EertweghA.J.: Low levels of circulating invariant natural killer T cellspredict poor clinical outcome in patients with head and neck squamouscell carcinoma. J. Clin. Oncol., 2007; 25: 862-868
  Google Scholar
• 10. Molling J.W., Moreno M., van der Vliet H.J., van den EertweghA.J., Scheper R.J., von Blomberg B.M., Bontkes H.J.: Invariant naturalkiller T cells and immunotherapy of cancer. Clin. Immunol., 2008;129: 182-194
  Google Scholar
• 11. Motohashi S., Ishikawa A., Ishikawa E., Otsuji M., Iizasa T., HanaokaH., Shimizu N., Horiguchi S., Okamoto Y., Fujii S., Taniguchi M.,Fujisawa T., Nakayama T.: A phase I study of in vitro expanded naturalkiller T cells in patients with advanced and recurrent non-smallcell lung cancer. Clin. Cancer Res., 2006; 12: 6079-6086
  Google Scholar
• 12. Motohashi S., Kobayashi S., Ito T., Magara K.K., Mikuni O., KamadaN., Iizasa T., Nakayama T., Fujisawa T., Taniguchi M.: PreservedIFN-α production of circulating Vα24 NKT cells in primary lung cancerpatients. Int. J. Cancer, 2002; 102: 159-165
  Google Scholar
• 13. Motohashi S., Okamoto Y., Yoshino I., Nakayama T.: Anti-tumorimmune responses induced by iNKT cell-based immunotherapyfor lung cancer and head and neck cancer. Clin. Immunol., 2011;140: 167-176
  Google Scholar
• 14. Nelke K.H., Pawlak W., Leszczyszyn J., Gerber H.: Photodynamictherapy in head and neck cancer. Postępy Hig. Med. Dośw., 2014;68: 119-128
  Google Scholar
• 15. Pantel M., Guntinas-Lichius O.: Laryngeal carcinoma: epidemiology,risk factors and survival. HNO, 2012; 60: 32-40
  Google Scholar
• 16. Ren J., Zhu D., Liu M., Sun Y., Tian L.: Downregulation of miR- 21 modulates Ras expression to promote apoptosis and suppressinvasion of laryngeal squamous cell carcinoma. Eur. J. Cancer, 2010;46: 3409-3416
  Google Scholar
• 17. Ritoe S.C., de Vegt F., Scheike I.M., Krabbe P.F., Kaanders J.H., vanden Hoogen F.J., Verbeek A.L., Marres H.A.: Effect of routine followupafter treatment for laryngeal cancer on life expectancy and mortality:results of a Markov model analysis. Cancer, 2007; 109: 239-247
  Google Scholar
• 18. Sakuishi K., Oki S., Araki M., Porcelli S.A., Miyake S., YamamuraT.: Invariant NKT cells biased for IL-5 production act as crucial regulatorsof inflammation. J. Immunol., 2007; 179: 3452-3462
  Google Scholar
• 19. Song L., Asgharzadeh S., Salo J., Engell K., Wu H.W., SpostoR., Ara T., Silverman A.M., DeClerck Y.A., Seeger R.C., MetelitsaL.S.: Vα24-invariant NKT cells mediate antitumor activity viakilling of tumor-associated macrophages. J. Clin. Invest., 2009;119: 1524-1536
  Google Scholar
• 20. Starska K., Głowacka E., Kulig A., Lewy-Trenda I., Bryś M., LewkowiczP.: The role of tumor cells in the modification of T lymphocytesactivity–the expression of the early CD69+, CD71+ and the late CD25+,CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamouscell laryngeal carcinoma. Part I. Folia Histochem. Cytobiol.,2011; 49: 579-592
  Google Scholar
• 21. Starska K., Głowacka E., Kulig A., Lewy-Trenda I., Bryś M., LewkowiczP.: Prognostic value of the immunological phenomena andrelationship with clinicopathological characteristics of the tumor- the expression of the early CD69+, CD71+ and the late CD25+, CD26+,HLA/DR+ activation markers on T CD4+ and CD8+ lymphocytes insquamous cell laryngeal carcinoma. Part II. Folia Histochem. Cytobiol.,2011; 49: 593-603
  Google Scholar
• 22. Sun W., Li W.J., Wu C.Y., Zhong H., Wen W.P.: CD45RA-Foxp3highbut not CD45RA+Foxp3low suppressive T regulatory cells increased inthe peripheral circulation of patients with head and neck squamouscell carcinoma and correlated with tumor progression. J. Exp. Clin.Cancer Res., 2014: 25: 33: 35
  Google Scholar
• 23. Tagawa T., Wu L., Anraku M., Yun Z., Rey-McIntyre K., de PerrotM.: Antitumor impact of interferon-γ producing CD1d-restrictedNKT cells in murine malignant mesothelioma. J. Immunother.,2013; 36: 391-399
  Google Scholar
• 24. Tahir S.M., Cheng O., Shaulov A., Koezuka Y., Bubley G.J., WilsonS.B., Balk S.P., Exley M.A.: Loss of IFN-γ production by invariant NK Tcells in advanced cancer. J. Immunol., 2001; 167: 4046-4050
  Google Scholar
• 25. Terabe M., Berzofsky J.A.: The role of NKT cells in tumor immunity.Adv. Cancer Res., 2008; 101: 277-348
  Google Scholar
• 26. van der Vliet H.J., Molling J.W., von Blomberg B.M., Kölgen W.,Stam A.G., de Gruijl T.D., Mulder C.J., Janssen H.L., Nishi N., vanden Eertwegh A.J., Scheper R.J., van Nieuwkerk C.J.: CirculatingVα24+Vβ11+ NKT cell numbers and dendritic cell CD1d expression inhepatitis C virus infected patients. Clin. Immunol., 2005; 114: 183-189
  Google Scholar
• 27. Wu L., Gabriel C.L., Parekh V.V., Van Kaer L.: Invariant naturalkiller T cells: innate-like T cells with potent immunomodulatoryactivities. Tissue Antigens, 2009; 73: 535-545
  Google Scholar
• 28. Yanagisawa K., Seino K., Ishikawa Y., Nozue M., Todoroki T.,Fukao K.: Impaired proliferative response of Vα 24 NKT cells fromcancer patients against α-galactosylceramide. J. Immunol., 2002;168: 6494-6499
  Google Scholar
• 29. Ziolkowska E., Wolowiec D., Cebula-Obrzut B., Blonski J.Z.,Smolewski P., Robak T., Korycka-Wolowiec A.: Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combinationwith rituximab on chronic lymphocytic leukemia cells in vitro.Postępy Hig. Med. Dośw., 2014; 68: 1433-1443
  Google Scholar

Pełna treść artykułu